Predictive performance of first trimester serum galectin‑13/PP‑13 in preeclampsia screening: A systematic review and meta‑analysis

Vasilache,Ingrid-Andrada; Carauleanu,Alexandru; Socolov,Demetra; Matasariu,Roxana; Pavaleanu,Ioana; Nemescu,Dragos

doi:10.3892/etm.2022.11297

Predictive performance of first trimester serum galectin‑13/PP‑13 in preeclampsia screening: A systematic review and meta‑analysis

Authors:
- Ingrid-Andrada Vasilache
- Alexandru Carauleanu
- Demetra Socolov
- Roxana Matasariu
- Ioana Pavaleanu
- Dragos Nemescu
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
Published online on: April 5, 2022 https://doi.org/10.3892/etm.2022.11297
Article Number: 370
Copyright: © Vasilache et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Placental protein‑13 (PP‑13) is a member of the galectin group involved in placental implantation, maternal artery remodeling, and placental inflammatory processes. Its levels are lower in the first trimester for pregnancies later affected by ischemic placental disease, and slowly increase during the second and third trimesters of pregnancy. The aim of the present meta‑analysis is to assess the predictive performance of PP‑13 in first trimester preeclampsia screening. PubMed, Web of Science, Scopus, Embase, BIOSIS, and Cochrane databases were used to find relevant studies. All prospective and retrospective observational studies that evaluated the accuracy of PP‑13 in predicting preeclampsia were assessed. The investigation revealed that the quantitative synthesis was based on 14 studies with a total number of 8,239 women. The pooled sensitivity of PP‑13 for the prediction of preeclampsia was 0.53 [95% (confidence interval (CI), 0.08‑0.99], and the pooled specificity was 0.83 (95% CI, 0.38‑1.29). Further analysis revealed a higher accuracy of PP‑13 for the screening of late‑onset preeclampsia [pooled sensitivity of 0.58 [95% CI, ‑0.17‑1.33) with a specificity of 0.85 (95% CI, 0.10‑1.60)] when compared with early‑onset preeclampsia [pooled sensitivity of 0.51 (95% CI, ‑0.04‑1.05) with a specificity of 0.88 (95% CI, 0.33‑1.42)]. In conclusion, PP‑13 appears to be a promising biomarker for evaluating the risk of developing preeclampsia during the first trimester of pregnancy. As a result, incorporating it into future predictive models is a viable option.

View Figures

View References

1	Ananth CV, Keyes KM and Wapner RJ: Pre-eclampsia rates in the United States, 1980-2010: Age-period-cohort analysis. BMJ. 347(f6564)2013.PubMed/NCBI View Article : Google Scholar
2	Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, et al: Galectins: A family of animal beta-galactoside-binding lectins. Cell. 76:597–598. 1994.PubMed/NCBI View Article : Google Scholar
3	Kang HG, Kim DH, Kim SJ, Cho Y, Jung J, Jang W and Chun KH: Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget. 7:68229–68241. 2016.PubMed/NCBI View Article : Google Scholar
4	Sammar M, Drobnjak T, Mandala M, Gizurarson S, Huppertz B and Meiri H: Galectin 13 (PP13) facilitates remodeling and structural stabilization of maternal vessels during pregnancy. Int J Mol Sci. 20(3192)2019.PubMed/NCBI View Article : Google Scholar
5	Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ. 372(n160)2021.PubMed/NCBI View Article : Google Scholar
6	National Center for Biotechnology Information (NCBI). PubMed database. https://pubmed.ncbi.nlm.nih.gov/. Accessed February 28, 2021.
7	Clarivate. Web of Science database. https://clarivate.com/webofsciencegroup/solutions/web-of-science/. Accessed on 28.02.2021.
8	Elsevier. Scopus database. https://www.scopus.com/home.uri. Accessed February 28, 2021.
9	Elsevier. Embase database. https://www.embase.com/landing?status=grey. Accessed February 28, 2021.
10	Clarivate. BIOSISCitationIndex. https://clarivate.com/webofsciencegroup/solutions/webodscience-biosis-citation-index/. Accessed February 28, 2021.
11	Cochrane Library. Cochrane database. https://www.cochranelibrary.com/. Accessed February 28, 2021.
12	Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM and Kleijnen J: The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 3(25)2003.PubMed/NCBI View Article : Google Scholar
13	Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA and Bossuyt PM: QUADAS-2 Group. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 155:529–536. 2011.PubMed/NCBI View Article : Google Scholar
14	DerSimonian R and Laird N: Meta-analysis in clinical trials revisited. Contemp Clin Trials. 45:139–145. 2015.PubMed/NCBI View Article : Google Scholar
15	Spencer K, Cowans NJ, Chefetz I, Tal J and Meiri H: First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 29:128–134. 2007.PubMed/NCBI View Article : Google Scholar
16	Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, Cuckle H and Wolf M: First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 197:35.e1–e7. 2007.PubMed/NCBI View Article : Google Scholar
17	Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H and Gibor Y: Placental protein 13 as an early marker for pre-eclampsia: A prospective longitudinal study. BJOG. 115:1465–1472. 2008.PubMed/NCBI View Article : Google Scholar
18	Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H and Harrington K: First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn. 29:781–789. 2009.PubMed/NCBI View Article : Google Scholar
19	Akolekar R, Syngelaki A, Beta J, Kocylowski R and Nicolaides KH: Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn. 29:1103–1108. 2009.PubMed/NCBI View Article : Google Scholar
20	Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H and Harrington K: First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk. Ultrasound Obstet Gynecol. 35:671–679. 2010.PubMed/NCBI View Article : Google Scholar
21	Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC and Visser GH: First-trimester placental protein 13 and placental growth factor: Markers for identification of women destined to develop early-onset pre-eclampsia. BJOG. 117:1384–1389. 2010.PubMed/NCBI View Article : Google Scholar
22	Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, Bower CR and Nelson DM: First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta. 32:598–602. 2011.PubMed/NCBI View Article : Google Scholar
23	Schneuer FJ, Nassar N, Khambalia AZ, Tasevski V, Guilbert C, Ashton AW, Morris JM and Roberts CL: First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: In-house study and systematic review. Placenta. 33:735–740. 2012.PubMed/NCBI View Article : Google Scholar
24	Deurloo KL, Linskens IH, Heymans MW, Heijboer AC, Blankenstein MA and van Vugt JM: ADAM12s and PP13 as first trimester screening markers for adverse pregnancy outcome. Clin Chem Lab Med. 51:1279–1284. 2013.PubMed/NCBI View Article : Google Scholar
25	Meiri H, Sammar M, Herzog A, Grimpel YI, Fihaman G, Cohen A, Kivity V, Sharabi-Nov A and Gonnen R: Prediction of preeclampsia by placental protein 13 and background risk factors and its prevention by aspirin. J Perinat Med. 42:591–601. 2014.PubMed/NCBI View Article : Google Scholar
26	Luo Q and Han X: Second-trimester maternal serum markers in the prediction of preeclampsia. J Perinat Med. 45:809–816. 2017.PubMed/NCBI View Article : Google Scholar
27	Asiltas B, Surmen-Gur E and Uncu G: Prediction of first-trimester preeclampsia: Relevance of the oxidative stress marker MDA in a combination model with PP-13, PAPP-A and beta-HCG. Pathophysiology. 25:131–135. 2018.PubMed/NCBI View Article : Google Scholar
28	Soongsatitanon A and Phupong V: Prediction of preeclampsia using first trimester placental protein 13 and uterine artery Doppler. J Matern Fetal Neonatal Med: Nov 16, 2020 (Epub ahead of print).
29	North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, Black MA, Taylor RS, Walker JJ, Baker PN and Kenny LC: Clinical risk prediction for pre-eclampsia in nulliparous women: Development of model in international prospective cohort. BMJ. 342(d1875)2011.PubMed/NCBI View Article : Google Scholar
30	Kliman HJ, Sammar M, Grimpel YI, Lynch SK, Milano KM, Pick E, Bejar J, Arad A, Lee JJ, Meiri H and Gonen R: Placental protein 13 and decidual zones of necrosis: An immunologic diversion that may be linked to preeclampsia. Reprod Sci. 19:16–30. 2012.PubMed/NCBI View Article : Google Scholar
31	Redman CW, Sargent IL and Staff AC: IFPA Senior award lecture: Making sense of pre-eclampsia-two placental causes of preeclampsia? Placenta. 35 (Suppl 1):S20–S25. 2014.PubMed/NCBI View Article : Google Scholar
32	Monte S: Biochemical markers for prediction of preclampsia: Review of the literature. J Prenat Med. 5:69–77. 2011.PubMed/NCBI